Previously, we identified Plk1 expression combined with the TP53 mutation status and the occurrence of hypoxic regions as a promising prognostic biomarker panel for NSCLC (Van den Bossche et al., 2017). The gene discussed is PLK1; the disease is non-small cell lung carcinoma.